{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T12:08:55Z","timestamp":1781093335207,"version":"3.54.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.abd.2026.501335","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:28:20Z","timestamp":1777530500000},"page":"501335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The efficacy and sustainability of a reduced risankizumab dose after achievement of low disease activity of psoriasis: a 24-week study"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5906-3976","authenticated-orcid":false,"given":"Gizem","family":"Pehlivan Uluta\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011fba","family":"\u00d6zk\u00f6k Akbulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alg\u00fcn","family":"Polat Ekinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2026.501335_bib0005","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2026.501335_bib0010","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2133.2010.10139.x","article-title":"Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy","volume":"164","author":"Papp","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2026.501335_bib0015","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14134","article-title":"Reduced doses of biological therapies in psoriasis may increase efficiency without decreasing drug survival","volume":"33","author":"Llamas-Velasco","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2026.501335_bib0020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2340\/00015555-2209","article-title":"Down-titration of adalimumab and etanercept in psoriatic patients: a multicentre observational study","volume":"96","author":"Piaserico","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2026.501335_bib0025","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/09546634.2020.1759769","article-title":"Deferred time of delivery of biologic therapies in patients with stabilized psoriasis leads to a 'perceived satisfaction': a multicentric study","volume":"33","author":"Di Altobrando","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2026.501335_bib0030","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ad.2015.02.003","article-title":"Dose modification in biologic therapy for moderate to severe Psoriasis: a descriptive analysis in a clinical practice setting","volume":"106","author":"Baniandr\u00e9s","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.abd.2026.501335_bib0035","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3815","article-title":"Evaluation of a one-step dose reduction strategy of adalimumab, etanercept and ustekinumab in patients with Psoriasis in daily practice","volume":"101","author":"Atalay","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2026.501335_bib0040","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the gu\u0131de randomized clinical trial","volume":"160","author":"Eyerich","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.abd.2026.501335_bib0045","doi-asserted-by":"crossref","first-page":"e713","DOI":"10.1111\/jdv.18182","article-title":"Is risankizumab as needed administration a good option for patients with plaque psoriasis?","volume":"36","author":"Gisondi","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2026.501335_bib0050","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.jaad.2021.04.093","article-title":"Extended dosing intervals of ixekizumab for psoriasis: a single-center, uncontrolled, prospective study","volume":"86","author":"Ye","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2026.501335_bib0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2340\/00015555-2571","article-title":"Adalimumab dose tapering in Psoriasis: predictive factors for maintenance of complete clearance","volume":"97","author":"Hansel","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2026.501335_bib0060","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15193","article-title":"Absolute Psoriasis area and severity \u0131ndex as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care","volume":"35","author":"Seidl","year":"2022","journal-title":"Dermatol Ther"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059626000486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059626000486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:40:48Z","timestamp":1781091648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059626000486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0365059626000486"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2026.501335","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and sustainability of a reduced risankizumab dose after achievement of low disease activity of psoriasis: a 24-week study","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2026.501335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501335"}}